Compare Incyte Corporation (INCY) vs Motorola Solutions Inc (MSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Motorola Solutions Inc — how do they compare? Incyte Corporation trades at $118.08 (market cap $23.11B), while Motorola Solutions Inc trades at $402.76 (market cap $68.13B). The key difference: Motorola Solutions Inc is far larger — about 2.9× Incyte Corporation's market cap, and Motorola Solutions Inc pays a 1.18% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | MSI | |
|---|---|---|
Market Cap | $23.11B | $68.13B |
Sector | Health | Technology |
52-Week High | $118.52 | $490.30 |
52-Week Low | $67.38 | $363.83 |
Enterprise Value | $19.13B | $76.83B |
Dividend Yield | — | 1.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
MSI trades at $412.34, down 0.23% on the day, with a neutral technical signal. The company shows strong profitability with a 17.61% net income margin and has beaten earnings estimates for three consecutive quarters. Recent developments include the $1.5 billion acquisition of D-Fend Solutions and expansion of AI capabilities for emergency response systems, indicating strategic growth in public safety technology.
The outlook remains positive with a consensus price target of $512.33, representing 24% upside potential. Key risks include high valuation multiples and significant investing cash outflows from acquisitions. Analyst sentiment is bullish with 70.59% buy ratings, though investors should monitor integration execution of recent deals and competitive pressures in the tech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Motorola Solutions Inc
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →
